Merck co uncorks pivotal victory 3b eye disease prospect

T2Covered by 1 source · first reported by Fierce Biotech / Fierce Healthcare / MedCity / GEN at 24 Sept, 12:27 UTC

Merck & Co.’s Brunello trial has hit its primary endpoint, shedding light on the effects of a trispecific diabetic macular edema (DME) drug candidate that the Big Pharma bought in a $3 billion takeover.

science

Sources

• T2Merck co uncorks pivotal victory 3b eye disease prospectFierce Biotech / Fierce Healthcare / MedCity / GEN24 Sept, 12:27